Advances in intravenous thrombolysis with tenecteplase in the ultra-time window
Достижения в области внутривенного тромболизиса тенектеплазой в сверхшироком временном окне
2026-02-18
SCID: 54.1/bkx3z7sd
Discuss with AI
intravenous thrombolysisischemic penumbralarge vessel occlusiontenecteplaseultra-time window thrombolysis
Figures from the paper
Abstract (AI)
Worldwide, stroke has become a significant public health concern, with ischemic strokes accounting for over 70% among all stroke types. Intravenous thrombolysis (IVT), as a traditional treatment method, is limited by a narrow 4.5-h time window, which restricts its application. The conception of a "tissue window" for imaging evaluation has prompted a change in treatment strategy in recent years, and the time window has been gradually expanded to 24 h. Tenecteplase (TNK), a third-generation thrombolytic medication with a long half-life, good fibrin specificity, and minimal risk of bleeding, has garnered significant research interest in ultra-time window thrombolysis. TNK is noninferior to alteplase (rt-PA) at 4.5 h and has a superior reperfusion rate in patients with large vessel occlusion in the anterior circulation, according to several phase III randomized controlled studies (e.g., AcT, TRACE-2, ORIGINAL). Ultra-time window studies (e.g., TRACE-3 and TIMELESS) have demonstrated that TNK has a positive safety profile and substantially enhances functional outcomes in patients who possess an ischemic penumbra detected by imaging screening for 4.5-24 h. Nevertheless, certain research (such as the CHABLIS-T II study) demonstrated that the application of ultra-time window intravenous thrombolysis improves reperfusion but doesn't improve the prognosis. Therefore, multicenter trials, coupled with neuroprotective medications or anti-inflammatory therapy, and dynamic imaging stratification are required to optimize intravenous thrombolysis strategies. This article serves as a reference for clinical practice and research direction by conducting a systematic review of the recent findings on ultra-time window thrombolysis in TNK.
Key Findings
1
At 4.5 hours, phase III trials found tenecteplase noninferior to alteplase; in anterior-circulation large-vessel occlusion, tenecteplase achieved superior reperfusion rates.
2
CHABLIS-T II found that ultra-time-window thrombolysis improved reperfusion without improving clinical prognosis, indicating the need for further multicenter trials, combination therapies, and dynamic imaging stratification.
3
Intravenous thrombolysis traditionally has a 4.5-hour treatment window, but imaging-defined ischemic tissue windows have expanded eligibility to 24 hours.
4
TRACE-3 and TIMELESS showed favorable safety and substantially improved functional outcomes with imaging-selected tenecteplase treatment 4.5–24 hours after onset.
5
Tenecteplase has a long half-life, high fibrin specificity, and low bleeding risk, supporting its investigation for ultra-time-window thrombolysis.
Research Object
ultra-time-window intravenous thrombolysis with tenecteplase in patients with ischemic stroke and imaging-detected ischemic penumbra
Research Subject
the safety, reperfusion efficacy, and functional outcomes of tenecteplase-based thrombolysis during the 4.5–24-hour window
Publication Details
Publication Date
2026-02-18
Journal
Publisher
ISSN
Cited by
2
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association2023
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 20212024
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy2024
Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection2024